US20170296667A1 - Caspofungin Acetate Formulations - Google Patents
Caspofungin Acetate Formulations Download PDFInfo
- Publication number
- US20170296667A1 US20170296667A1 US15/474,531 US201715474531A US2017296667A1 US 20170296667 A1 US20170296667 A1 US 20170296667A1 US 201715474531 A US201715474531 A US 201715474531A US 2017296667 A1 US2017296667 A1 US 2017296667A1
- Authority
- US
- United States
- Prior art keywords
- composition
- caspofungin acetate
- amino acid
- mass ratio
- caspofungin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010020326 Caspofungin Proteins 0.000 title claims abstract description 248
- 239000000203 mixture Substances 0.000 title claims abstract description 219
- 229960000730 caspofungin acetate Drugs 0.000 title claims abstract description 215
- OGUJBRYAAJYXQP-IJFZAWIJSA-N vuw370o5qe Chemical compound CC(O)=O.CC(O)=O.C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 OGUJBRYAAJYXQP-IJFZAWIJSA-N 0.000 title claims abstract description 214
- 238000009472 formulation Methods 0.000 title description 41
- 150000001413 amino acids Chemical class 0.000 claims abstract description 117
- 239000008247 solid mixture Substances 0.000 claims abstract description 75
- 239000007788 liquid Substances 0.000 claims abstract description 64
- 239000007787 solid Substances 0.000 claims abstract description 16
- 239000002904 solvent Substances 0.000 claims abstract description 15
- 229940024606 amino acid Drugs 0.000 claims description 109
- 235000001014 amino acid Nutrition 0.000 claims description 109
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 93
- 239000004475 Arginine Substances 0.000 claims description 52
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 52
- 229960003121 arginine Drugs 0.000 claims description 52
- 235000009697 arginine Nutrition 0.000 claims description 52
- 239000004471 Glycine Substances 0.000 claims description 44
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 25
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 20
- 229960001230 asparagine Drugs 0.000 claims description 20
- 235000009582 asparagine Nutrition 0.000 claims description 20
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 17
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 17
- OLYPWXRMOFUVGH-LURJTMIESA-N N(2)-methyl-L-lysine Chemical compound CN[C@H](C(O)=O)CCCCN OLYPWXRMOFUVGH-LURJTMIESA-N 0.000 claims description 16
- 229960003104 ornithine Drugs 0.000 claims description 13
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 12
- 239000004472 Lysine Substances 0.000 claims description 12
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 12
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 12
- 235000018977 lysine Nutrition 0.000 claims description 12
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims description 8
- 229960002684 aminocaproic acid Drugs 0.000 claims description 8
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 7
- 229960003646 lysine Drugs 0.000 claims description 7
- JJMDCOVWQOJGCB-UHFFFAOYSA-N 5-aminopentanoic acid Chemical compound [NH3+]CCCCC([O-])=O JJMDCOVWQOJGCB-UHFFFAOYSA-N 0.000 claims description 6
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 6
- 150000003141 primary amines Chemical class 0.000 claims description 6
- 150000003335 secondary amines Chemical group 0.000 claims description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- QFRURJKLPJVRQY-UHFFFAOYSA-N 3-Aminopentanoic acid Chemical compound CCC(N)CC(O)=O QFRURJKLPJVRQY-UHFFFAOYSA-N 0.000 claims description 3
- UQXNEWQGGVUVQA-UHFFFAOYSA-N 8-aminooctanoic acid Chemical compound NCCCCCCCC(O)=O UQXNEWQGGVUVQA-UHFFFAOYSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 3
- 235000004279 alanine Nutrition 0.000 claims description 3
- 229960005261 aspartic acid Drugs 0.000 claims description 3
- 235000003704 aspartic acid Nutrition 0.000 claims description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
- 229960002433 cysteine Drugs 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 3
- 235000004554 glutamine Nutrition 0.000 claims description 3
- 229960002885 histidine Drugs 0.000 claims description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
- 229960000310 isoleucine Drugs 0.000 claims description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 3
- 229960003136 leucine Drugs 0.000 claims description 3
- 229930182817 methionine Natural products 0.000 claims description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
- 239000004474 valine Substances 0.000 claims description 3
- 229960002449 glycine Drugs 0.000 claims 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 2
- 229960002989 glutamic acid Drugs 0.000 claims 2
- 229960002743 glutamine Drugs 0.000 claims 2
- 229960004452 methionine Drugs 0.000 claims 2
- 229960003034 caspofungin Drugs 0.000 abstract description 22
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 abstract description 22
- 239000012535 impurity Substances 0.000 description 81
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 30
- 229940050526 hydroxyethylstarch Drugs 0.000 description 30
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 27
- 238000003860 storage Methods 0.000 description 25
- 239000000126 substance Substances 0.000 description 24
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 20
- 229930195725 Mannitol Natural products 0.000 description 20
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 20
- 229930006000 Sucrose Natural products 0.000 description 20
- 239000000594 mannitol Substances 0.000 description 20
- 235000010355 mannitol Nutrition 0.000 description 20
- 239000005720 sucrose Substances 0.000 description 20
- 239000000546 pharmaceutical excipient Substances 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000008365 aqueous carrier Substances 0.000 description 14
- 229940080858 cancidas Drugs 0.000 description 12
- JYIKNQVWKBUSNH-OGZDCFRISA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCCC(C)CC(C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-OGZDCFRISA-N 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 238000004108 freeze drying Methods 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000006641 stabilisation Effects 0.000 description 7
- 238000011105 stabilization Methods 0.000 description 7
- 239000003381 stabilizer Substances 0.000 description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 239000008215 water for injection Substances 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 206010017533 Fungal infection Diseases 0.000 description 4
- 208000031888 Mycoses Diseases 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000000087 stabilizing effect Effects 0.000 description 4
- 108010049047 Echinocandins Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 239000003429 antifungal agent Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- -1 hydrochloric Chemical class 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 238000007711 solidification Methods 0.000 description 3
- 230000008023 solidification Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 159000000021 acetate salts Chemical group 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000008228 bacteriostatic water for injection Substances 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000012792 lyophilization process Methods 0.000 description 2
- 239000012931 lyophilized formulation Substances 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 125000003156 secondary amide group Chemical group 0.000 description 2
- 239000008354 sodium chloride injection Substances 0.000 description 2
- 239000008227 sterile water for injection Substances 0.000 description 2
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
- UHPDQDWXMXBLRX-DMTCNVIQSA-N (2s,3r)-2,5-diamino-3-hydroxypentanoic acid Chemical compound NCC[C@@H](O)[C@H](N)C(O)=O UHPDQDWXMXBLRX-DMTCNVIQSA-N 0.000 description 1
- 0 *CC*[C@@](*C([C@@](*(CC1)C([C@@](*C([C@@](*C([C@](C[C@](C2)O)*2C([C@@](*C(C(*C(CCCCCCCCC(CC(C*)N)N)=O)C2)=O)[C@@](N)O)=O)=O)[C@@]([C@](c(cc3)ccc3O)O)O)=O)[C@@](CC*)O)=O)[C@]1O)=O)[C@@]2O Chemical compound *CC*[C@@](*C([C@@](*(CC1)C([C@@](*C([C@@](*C([C@](C[C@](C2)O)*2C([C@@](*C(C(*C(CCCCCCCCC(CC(C*)N)N)=O)C2)=O)[C@@](N)O)=O)=O)[C@@]([C@](c(cc3)ccc3O)O)O)=O)[C@@](CC*)O)=O)[C@]1O)=O)[C@@]2O 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 206010056519 Abdominal infection Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- ONXPDKGXOOORHB-BYPYZUCNSA-N N(5)-methyl-L-glutamine Chemical compound CNC(=O)CC[C@H](N)C(O)=O ONXPDKGXOOORHB-BYPYZUCNSA-N 0.000 description 1
- 206010058803 Oesophageal infection Diseases 0.000 description 1
- 206010034668 Peritoneal infections Diseases 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010042938 Systemic candida Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 208000017773 candidemia Diseases 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
- 229960003804 efavirenz Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000005496 eutectics Effects 0.000 description 1
- 150000002194 fatty esters Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000009085 invasive aspergillosis Diseases 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 210000003281 pleural cavity Anatomy 0.000 description 1
- DQXPFAADCTZLNL-FXDJFZINSA-N pneumocandin B0 Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CC(N)=O)=CC=C(O)C=C1 DQXPFAADCTZLNL-FXDJFZINSA-N 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000005837 radical ions Chemical class 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Definitions
- a variety of fungal infections can occur in patients due to pathogenic Candida or Aspergillus fungus species.
- fungal infections include candidemia, candidiasis (including esophageal infections, abdominal infections, pleural space infections and peritoneal infections), and invasive aspergillosis.
- candidemia candidiasis
- candidiasis including esophageal infections, abdominal infections, pleural space infections and peritoneal infections
- invasive aspergillosis Early antifungal agents typically attacked the inner cell membrane of the invasive fungus. These early agents had a variety of drawbacks, however, including toxic side effects, drug-drug interactions, variations in efficacy between patients, and fungal resistance.
- echniocandins which treat fungal infections through a different mechanism—inhibition of the enzyme that forms ⁇ -(1,3)-D-glucan, an essential component of the fungal outer cell wall. Since ⁇ -(1,3)-D-glucan does not occur naturally in the cell walls of mammals, the action of echinocandins is unlikely to be harmful to the cells of an infected patient. Due to the difference in their mechanism of action relative to earlier agents, echinocandins have not experienced wide resistance by target fungi.
- Caspofungin acetate was the first of the echinocandins to be approved in the U.S. for use as an antifungal agent.
- the full name for caspofungin acetate is reported as 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N 2 -(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine] pneumocandin B 0 diacetate (salt), and a representative chemical structure of caspofungin acetate is shown in FIG. 1 .
- An approved treatment regimen for adults includes an initial administration of 70 milligrams (mg) caspofungin acetate, followed by daily administration of 50 mg caspofungin acetate, where each administration is performed through intravenous infusion over 1 hour.
- caspofungin acetate As caspofungin acetate has poor oral bioavailability, it typically has been provided to medical personnel as a lyophilized solid, which is then reconstituted before intravenous administration to a patient.
- a formulation of caspofungin acetate that is commercially available at present is sold under the CANCIDAS® trademark.
- CANCIDAS® for Injection (Merck & Co, Inc.; Whitehouse Station, N.J., USA) is currently available as a lyophilized powder.
- CANCIDAS® is available in vials containing either 54.6 mg or 75.6 mg of caspofungin acetate, in combination with sucrose and mannitol, and including acetic acid and sodium hydroxide as pH modifiers.
- CANCIDAS® is reconstituted for administration by combining the lyophilized powder with 10.8 milliliters (mL) of a reconstitution liquid (such as 0.9% sodium chloride), to provide a solution having a caspofungin acetate concentration of either 7 milligrams per milliliter (mg/mL) or 5 mg/mL.
- a reconstitution liquid such as 0.9% sodium chloride
- caspofungin acetate One challenge associated with the commercially available formulation of caspofungin acetate is its instability, including its instability at ambient temperatures. Degradation products of caspofungin acetate at room temperature ( ⁇ 25° C.) include various dimers of caspofungin, as well as other substances. Current protocols require caspofungin acetate to be stored at ⁇ 70° C. ( ⁇ 10° C.), and require the lyophilized CANCIDAS® formulation to be stored at temperatures of 2-8° C. A reconstituted liquid formed from the CANCIDAS® formulation must be diluted within one hour, and then either administered within 24 hours or stored at 2-8° C. for up to 48 hours. These temperature and time constraints present potential difficulties for effective administration of caspofungin acetate, both in medical professional settings and in outpatient settings. See, for example, Tsiouris, Maria et al. “Stability and compatibility of reconstituted caspofungin in select elastomeric infusion devices”, International Journal of Pharmaceutical Compounding (2010), 14(5),
- the pH modifiers acetic acid and sodium hydroxide were eliminated from the CANCIDAS® formulation, and the resulting formulations had improved stability at ambient temperatures. Lyophilized formulations were more stable with respect to caspofungin at 25° C. for 12 weeks, and reconstituted solutions of the formulations were more stable with respect to the caspofungin at 25° C. for 2 days. See US 2009/0170753, paragraphs [0080], [0204]-[0207] and [0214]-[0217].
- sucrose and mannitol in the CANCIDAS® formulation were replaced with a non-reducing sugar such as trehalose, and the resulting formulations had improved stability at ambient temperatures. Lyophilized formulations containing trehalose more were stable with respect to caspofungin at 30° C. for up to 72 weeks, and at 40° C. for up to 24 weeks. See US 2010/0137197, paragraphs [0114]-[0119].
- caspofungin acetate formulations that can be stored as lyophilized solids without the need for control of the surrounding temperature.
- a lyophilized formulation of caspofungin acetate it is desirable for a lyophilized formulation of caspofungin acetate to be stable at temperatures of 25° C. or higher for a period of from 6 months to 2 years.
- such stabilized formulations would be convenient to prepare, store, reconstitute and administer.
- the invention provides a composition including caspofungin acetate and at least one amino acid, where the composition is a solid.
- composition including from 50 to 70 mg caspofungin acetate, and arginine.
- the mass ratio of arginine to caspofungin acetate is from 2:5 to 3:1, and the composition is a solid.
- composition formed by a method including forming a liquid mixture that includes a solvent, caspofungin acetate and at least one amino acid, and lyophilizing the liquid mixture to form a solid composition.
- FIG. 1 depicts a chemical structure of caspofungin acetate.
- FIGS. 2A and 2B depict chemical structures of examples of amino acids.
- Lyophilized formulations that include caspofungin acetate and an amino acid can protect caspofungin acetate from degradation. These formulations may be stored at room temperature for up to two years, and thus may not require storage in a refrigerator or freezer prior to use. Reconstitution of the lyophilized formulations with a carrier liquid can yield an injectable liquid that may be used to administer caspofungin acetate.
- a composition may include caspofungin acetate, at least one amino acid and optionally one or more other substances, where the composition is a solid.
- the solid composition may be prepared by forming a liquid mixture including a solvent, caspofungin acetate and at least one amino acid, and then lyophilizing the mixture.
- the resulting solid composition may be used in administering caspofungin acetate to a patient by combining the composition with an aqueous carrier to form a solution or emulsion, which, for example, can be injected into a patient.
- Caspofungin acetate is a salt of one equivalent of caspofungin and two equivalents of acetic acid, providing an empirical formula of C 52 H 88 N 10 O 15 .2C 2 H 4 O 2 , and a formula weight of 1,213.42 grams per mole.
- the chemical structure shown in FIG. 1 represents caspofungin acetate in its associated form.
- Caspofungin acetate may dissociate from one or both of its equivalents of acetic acid in the presence of a solvent; however, the salt still includes both the cyclic caspofungin and the acetic acid species.
- the term “caspofungin acetate” includes both an associated combination of caspofungin and acetic acid, as well as caspofungin and acetic acid in a dissociated state, such as may occur when the salt is combined with a solvent.
- Caspofungin acetate does not include salts of caspofungin with substances other than acetic acid.
- caspofungin can form pharmaceutically acceptable salts with substances including cations such as sodium, potassium, aluminum, calcium, lithium, magnesium and zinc; acids such as hydrochloric, hydrobromic, phosphoric, sulfuric, maleic, citric, tartaric, succinic, oxalic, malic, glutamic, lactic, propionic and pamoic acids; and bases such as ammonia, ethylenediamine, N-methyl-glutamine, lysine, arginine, ornithine, choline, N,N′-dibenzylethylene-diamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)aminomethane and tetramethyl-ammonium hydroxide.
- a solid composition that includes caspofungin acetate and an amino acid may include an amount of caspofungin acetate that is sufficient for a single initial dose of caspofungin acetate, or an amount sufficient for a daily maintenance dose of caspofungin acetate.
- a solid composition that includes caspofungin acetate and an amino acid may include an amount of caspofungin acetate that is sufficient for two or more initial doses of caspofungin acetate, or an amount sufficient for two or more daily maintenance doses of caspofungin acetate.
- the amount of caspofungin acetate in the composition may be a different therapeutic amount.
- the amount of caspofungin acetate in the composition may be an amount sufficient for half of a single initial dose, or for half of a daily maintenance dose.
- a solid composition that includes caspofungin acetate and an amino acid may include from 10 to 150 milligrams (mg) caspofungin acetate.
- the composition includes from 25 to 100 mg caspofungin acetate, or from 50 to 70 mg caspofungin acetate.
- Presently preferred amounts of caspofungin acetate in the composition include about 50 mg and about 70 mg.
- a solid composition that includes caspofungin acetate and an amino acid includes one or more amino acids, which are compounds containing at least one carboxylic acid group [—C( ⁇ O)OH] and at least one primary or secondary amine group [—NH 2 or —RNH, where —R is a molecular entity other than —H], but lacking a secondary amide group [—C( ⁇ O)—NH—].
- FIG. 1 A solid composition that includes caspofungin acetate and an amino acid includes one or more amino acids, which are compounds containing at least one carboxylic acid group [—C( ⁇ O)OH] and at least one primary or secondary amine group [—NH 2 or —RNH, where —R is a molecular entity other than —H], but lacking a secondary amide group [—C( ⁇ O)—NH—].
- FIG. 2 depicts chemical structures of examples of amino acids, including alanine 202 , 4-aminobutanoic acid 204 , 3-aminopentanoic acid 206 , 5-aminopentanoic acid 208 , 6-aminohexanoic acid 210 , 8-aminooctanoic acid 212 , arginine 214 , aspartic acid 216 , asparagine 218 , cysteine 220 , glutamic acid 222 , glutamine 224 , glycine 226 , histidine 228 , isoleucine 230 , leucine 232 , lysine 234 , methionine 236 , methyl lysine 238 , ornithine 240 , phenylalanine 242 , proline 244 , serine 246 , threonine 248 , tryptophan 250 , tyrosine 252 and valine 254 .
- presently preferred amino acids for use in the solid compositions that include caspofungin acetate and at least one amino acid include 6-aminohexanoic acid 210 , arginine 214 , asparagine 218 , glycine 226 , lysine 234 , methyl lysine 238 , and ornithine 240 .
- a solid composition that includes caspofungin acetate and an amino acid may include one or more amino acids that contain at least two primary or secondary amine groups. Examples of amino acids containing at least two primary or secondary amine groups include arginine 214 , asparagine 218 , lysine 234 , methyl lysine 238 , and ornithine 240 .
- a solid composition including caspofungin acetate and an amino acid may be more stable than a solid composition including caspofungin acetate, mannitol and sucrose, such as the CANCIDAS® formulation (Merck & Co, Inc.). It is presently believed that solid compositions that include caspofungin acetate and an amino acid may be able to protect caspofungin acetate from degradation for a year or longer at room temperature ( ⁇ 25° C.), and for 6 months or longer at elevated temperatures.
- the amino acids arginine, asparagine and glycine can stabilize caspofungin acetate in solid compositions.
- Table 1 lists the results of stability analyses of lyophilized compositions of caspofungin acetate with arginine 214 , asparagine 218 and glycine 226 , and for a conventional lyophilized composition of caspofungin acetate with mannitol and sucrose.
- 50 mg caspofungin acetate was combined with the listed amino acid and with water for injection (USP), and the pH was adjusted to about 6.0. The aqueous mixtures were then lyophilized to provide solid powders.
- the solid composition having a mass ratio of arginine 214 to caspofungin acetate of 2:1 had the lowest level of impurities of the compositions listed in Table 1, from the initial days of the analysis and up to 56 days at 40° C. When stored at 5° C., 25° C. (room temperature), and 40° C. for 29 days, the impurity levels for this composition were only 0.61%, 0.65% and 0.91% respectively.
- This 2:1 arginine composition was more stable than the conventional mannitol and sucrose composition at each time and temperature for which comparative results are listed.
- this 2:1 arginine composition When subjected to extended storage for 8 weeks (56 days) at an elevated temperature of 40° C., this 2:1 arginine composition maintained a total impurity level of 1.37%, which is acceptable under the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Based on this acceptable stability under these accelerated aging conditions, it is presently believed that a solid composition including caspofungin acetate and arginine in a 2:1 mass ratio of amino acid to caspofungin acetate will be stable for up to 2 years at room temperature, and will be stable for 6 months or longer at 40° C.
- the effect of arginine 214 on the stability of caspofungin acetate in a solid composition appeared to be related to the relative amount of amino acid in the composition.
- the solid composition having a mass ratio of arginine to caspofungin acetate of 1:1 had a higher level of impurities than did the solid composition having a mass ratio of arginine to caspofungin acetate of 2:1, at each time and temperature for which comparative results are listed.
- the composition having the lower mass ratio of arginine to caspofungin acetate of 1:1 was still more stable than the conventional mannitol and sucrose composition at each temperature for which comparative results are listed.
- the stabilizing effect of asparagine 218 with regard to caspofungin acetate in a solid composition was less than the stabilizing effect of arginine.
- the solid compositions having mass ratios of asparagine to caspofungin acetate of 2:5 or 3:5 had higher levels of impurities than did the solid compositions having a mass ratio of arginine to caspofungin acetate of 2:1 or 1:1, at each time and temperature for which comparative results are listed.
- Compositions having a mass ratio of arginine to caspofungin acetate greater than 3:5 were not analyzed due to the lower aqueous solubility of asparagine in comparison to arginine.
- the stability of caspofungin acetate in compositions containing asparagine was comparable to that of the conventional mannitol and sucrose composition.
- the stabilizing effect of glycine 226 with regard to caspofungin acetate in a solid composition was less than the stabilizing effects of either arginine or asparagine.
- the solid composition having a mass ratio of glycine to caspofungin acetate of 1:1 had higher levels of impurities than did the solid compositions containing arginine or asparagine, at each time and temperature for which comparative results are listed.
- the mass ratio of glycine to caspofungin acetate could be higher than 1:1, such as 2:1 or 3:1.
- compositions of caspofungin acetate with glycine were still more stable overall than the conventional mannitol and sucrose composition when stored for 29 days at 40° C.
- a variety of amino acids other than arginine, asparagine and glycine also can stabilize caspofungin acetate in solid compositions.
- Table 2 lists the results of stability analyses of lyophilized compositions of caspofungin acetate with the amino acids 6-aminohexanoic acid 210 , arginine 214 , glycine 226 , lysine 234 , methyl lysine 238 and ornithine 240 .
- 50 mg caspofungin acetate was combined with the listed amino acid and with water for injection (USP), and the pH was adjusted. The aqueous mixtures were then lyophilized to provide solid powders.
- the composition having a mass ratio of arginine 214 to caspofungin acetate of 1:1 had the lowest level of impurities at elevated temperatures of 40° C. and 55° C., maintaining total impurity levels below 5% for the times and temperatures listed.
- the compositions containing 6-aminohexanoic acid 210 , lysine 234 , methyl lysine 238 or ornithine 240 were less stable than the arginine composition, having total impurity levels of 5.87%-13.80% at an elevated temperature of 40° C. for 4 weeks, and total impurity levels of 16.65%-33.38% at an elevated temperature of 55° C. for 2 weeks.
- the composition containing glycine 226 was the least stable of the amino acid compositions, having a total impurity level of 28.88% at an elevated temperature of 40° C. for 4 weeks, and a total impurity level of 44.70% at an elevated temperature of 55° C. for 2 weeks.
- Arginine can be used in different amounts relative to the amount of caspofungin acetate in solid compositions.
- Table 3 lists the results of stability analyses of lyophilized compositions of caspofungin acetate having mass ratios of arginine 214 to caspofungin acetate of 1:1 or 2:1.
- 50 mg caspofungin acetate was combined with the listed amino acid and with water for injection (USP), and the pH was adjusted. The aqueous mixtures were then lyophilized to provide solid powders. Samples of each solid composition were sealed in vials at temperatures of 25° C., 40° C. or 55° C.
- the stability of the caspofungin acetate in the compositions over time at each temperature was determined by analyzing samples by HPLC and then calculating the total amount of relevant impurities detected in each HPLC analysis by peak area percent, as described above with regard to the results of Table 1.
- Table 3 lists the percent total impurities measured for the lyophilized compositions.
- the solid compositions having mass ratios of arginine 214 to caspofungin acetate of 1:1 or 2:1 listed in Table 3 had good stability of the caspofungin acetate. When stored at 40° C. for up to 12 weeks, each of the listed compositions maintained total impurity levels below 3%. When stored at 55° C., the composition having an alkaline pH upon reconstitution had slightly less stability of the caspofungin acetate than did the compositions having acidic pH's. Each of the listed compositions, however, maintained total impurity levels below 5.5% when stored at 55° C. for up to 4 weeks.
- the stabilization of caspofungin acetate by amino acids is surprising and unexpected, as shown by comparing the stabilities of solid compositions of caspofungin acetate in combination with a typical lyophilization stabilizing agent and/or glycine.
- Solid compositions of caspofungin acetate containing hydroxyethyl starch (HES) were less stable than were solid compositions of caspofungin acetate containing glycine.
- HES a typical lyophilization stabilizing agent
- the improvement in caspofungin acetate stabilization that occurs when HES is replaced with glycine is not due to a simple replacement of one known stabilizing agent with another stabilizing agent.
- glycine was the least effective stabilizer of the amino acids listed in Tables 1 and 2 above, the improvement in stabilization achieved by replacing the HES with an amino acid is not a result of optimization of the amino acid composition.
- Table 4 lists the results of stability analyses of lyophilized compositions of caspofungin acetate with HES and/or glycine.
- 50 mg caspofungin acetate was combined with the listed excipient(s) and with water for injection (USP), and the pH was adjusted to about 6.0. The aqueous mixtures were then lyophilized to provide solid powders. Samples of each formulation were sealed in vials at temperatures of 5° C., 25° C. or 40° C. The stability of the caspofungin acetate in the formulations over time at each temperature was determined by analyzing samples by HPLC and then calculating the total amount of relevant impurities detected in each HPLC analysis by peak area percent, as described above with regard to the results of Table 1. Table 4 lists the percent total impurities for lyophilized formulations of caspofungin acetate with the excipients HES and/or glycine.
- the HES formulation (mass ratio of HES to caspofungin acetate of 2:1) had a high level of impurities even at the beginning of the analysis.
- the 2.10% impurity level at the beginning of the analysis rose to 3.40%, 10.15% and 24.71% after storage for 28 days at 5° C., for 28 days at 25° C. (room temperature), and for 14 days at 40° C., respectively.
- Substituting the remaining HES excipient with glycine further reduced the amount of impurities in the formulation.
- the formulations with glycine but without HES as an excipient had impurity levels of approximately 1% or lower at the beginning of the analysis.
- the stabilization of caspofungin acetate due to removal of HES was observed even when the concentration of the amino acid was lower than the concentration of the HES.
- the formulation having a mass ratio glycine to caspofungin acetate of 1:1 and a moisture content of 0.53% corresponded to removing the HES excipient from the formulation having a mass ratio of HES to glycine to caspofungin acetate of 1:1:1.
- caspofungin acetate was less stable in a formulation having a glycine to caspofungin acetate mass ratio of 1:1 than in a formulation having a glycine to caspofungin acetate mass ratio of 2:1, the caspofungin acetate was still more stable when combined with glycine as the only excipient than when HES was the only excipient.
- the stabilization of lyophilized caspofungin acetate in combination with an amino acid may be affected by the water content of the lyophilized solid.
- Table 3 an approximately 2-fold increase in water content (from 0.53% to 1.29%) of the lyophilized formulation containing a 1:1 mass ratio of glycine to caspofungin acetate resulted in a decrease in caspofungin acetate stability. Even this decreased stability, however, was an improvement over the formulations that included HES as an excipient but that had a lower moisture content.
- the surprising and unexpected stabilization of caspofungin by amino acids may be used to prepare solid compositions including caspofungin acetate that are more stable than a conventional solid composition including caspofungin acetate, mannitol and sucrose.
- the surprising and unexpected stabilization of caspofungin by amino acids may be used to prepare solid compositions including caspofungin acetate that are able to protect caspofungin acetate from degradation for a year or longer at room temperature ( ⁇ 25° C.), and for 6 months or longer at elevated temperatures.
- a solid composition that includes caspofungin acetate and an amino acid may include an amount of the amino acid sufficient to stabilize the caspofungin acetate.
- the amount of the amino acid in the composition is at most an amount that will dissolve in a sample of aqueous liquid, such as a volume of aqueous liquid used for reconstitution of the solid composition.
- a solid composition that includes caspofungin acetate and an amino acid may include from 20 to 350 mg of the amino acid.
- the amount of amino acid in the composition preferably is from 20 to 250 mg, from 20 to 150 mg, from 20 to 100 mg, from 30 to 250 mg, from 30 to 150 mg, or from 30 to 100 mg.
- the amount of amino acid in the composition preferably is from 28 to 350 mg, from 28 to 210 mg, from 28 to 140 mg, from 42 to 350 mg, from 42 to 210 mg, or from 42 to 140 mg.
- a solid composition that includes caspofungin acetate and an amino acid may have a mass ratio of amino acid to caspofungin of at least 2:5, where the mass of amino acid in the ratio accounts for all amino acid species present in the solid composition.
- the mass ratio of amino acid to caspofungin acetate is at least 3:5, at least 1:1 or at least 2:1.
- the mass ratio of amino acid to caspofungin acetate is at most 3:1 or at most 2:1.
- the mass ratio of amino acid to caspofungin acetate is from 2:5 to 3:1, from 3:5 to 2:1, or from 1:1 to 3:1.
- a solid composition that includes caspofungin acetate and an amino acid may further include an acid and/or a base.
- the pH of a saturated solution of caspofungin acetate in water is about 6.6 (CANCIDAS® prescribing information, Merck Sharp & Dohme Corp., June, 2010, p. 14).
- the amount of the acid and/or base may be an amount sufficient to provide a pH in the range of 5 to 7 or of 6 to 7 when the composition is reconstituted in 10.8 mL of an aqueous liquid.
- the amount of the acid and/or base may be an amount sufficient to provide a pH in the range of 5 to 7 or of 6 to 7 when the composition is reconstituted in 10.8 mL of 0.9% aqueous sodium chloride (USP), sterile water for injection, or bacteriostatic water for injection containing either 0.9% benzyl alcohol or a combination of methylparaben and propylparaben.
- USP 0.9% aqueous sodium chloride
- sterile water for injection or bacteriostatic water for injection containing either 0.9% benzyl alcohol or a combination of methylparaben and propylparaben.
- Presently preferred acids include hydrochloric acid.
- Presently preferred bases include sodium hydroxide.
- a solid composition that includes caspofungin acetate and an amino acid may further include one or more other substances.
- Non-limiting examples of other substances include bulking agents, carriers, diluents, fillers, salts, buffers, stabilizers, solubilizers, preservatives, antioxidants, and tonicity contributors.
- Substances that may be useful in formulating pharmaceutically acceptable compositions, and methods of forming such compositions are described for example in Remington: The Science and Practice of Pharmacy, 20th Ed., ed. A. Gennaro, Lippincott Williams & Wilkins, 2000, and in Kibbe, “Handbook of Pharmaceutical Excipients,” 3 rd Edition, 2000.
- the solid composition does not include dextrose, as caspofungin acetate is reportedly unstable when reconstituted in a liquid containing dextrose. See CANCIDAS® prescribing information, Merck Sharp & Dohme Corp., June, 2010, p. 3.
- a solid composition including caspofungin acetate, at least one amino acid and optionally one or more other substances may be prepared by forming a liquid mixture that includes a solvent, caspofungin acetate, amino acid(s) and optionally one or more other substances, and lyophilizing the liquid mixture.
- the lyophilizing may include freeze-drying the liquid mixture to provide a solid composition.
- the liquid mixture may include caspofungin acetate and an amino acid in the amounts described above.
- the liquid mixture may further include an acid, a base and/or one or more other substances, as described above.
- the liquid mixture may include from 0.1 to 5 mL solvent, from 10 to 150 mg caspofungin acetate, and from 20 to 350 mg amino acid.
- the liquid mixture may include from 0.5 to 2 mL solvent, from 25 to 100 mg caspofungin acetate, and from 20 to 350 mg amino acid.
- the liquid mixture may include from 0.75 to 1.5 mL solvent, from 50 to 70 mg caspofungin acetate, and from 20 to 350 mg amino acid.
- the mass ratio of amino acid to caspofungin acetate in the liquid mixture may be from 2:5 to 3:1, from 3:5 to 2:1, or from 1:1 to 3:1.
- the solvent, caspofungin acetate, amino acid, optional acid, optional base and one or more other optional substances may be combined in any order when forming the liquid mixture.
- a liquid mixture may be formed by adding the caspofungin acetate and the amino acid(s) to a container including the solvent, and then adding the acid and/or base to achieve the desired pH in the liquid mixture.
- the liquid mixture preferably has a pH of from 6 to 7. A presently preferred pH of the liquid mixture is 6 ⁇ 1.
- the liquid mixture including the solvent, caspofungin acetate, amino acid, and any other optional ingredients may be lyophilized to form a solid composition, such as by subjecting the liquid mixture to freeze-drying. Freeze-drying of the liquid mixture may include maintaining the liquid mixture in an inert atmosphere, such as nitrogen or argon. Preferably the liquid mixture is placed in glass vials prior to lyophilization, and the amount of the liquid mixture in each vial is based on the amount of caspofungin acetate intended to be present in the final solid composition in the vial.
- the temperature of the liquid mixture is lowered to a temperature at or below the solidification point of the liquid mixture. If the liquid mixture forms a glass when cooled, the solidification point is the glass transition temperature. If the liquid mixture forms crystals when cooled, the solidification point is the eutectic point.
- the solidified mixture is then dried under vacuum. Typically, the drying process includes a primary drying step in which the temperature of the solidified mixture is raised gradually while most of the water is removed from the mixture by the vacuum, and a secondary drying step in which the temperature of the solidified mixture is raised further while residual moisture is removed from the mixture by the vacuum. The temperature is kept at or below the desired storage temperature for the final solid composition. Lyophilization typically is complete within 48 hours, but may require additional time.
- the solid composition resulting from the lyophilization typically is sealed for later use. Details regarding the lyophilization process may be found, for example, in Remington: The Science and Practice of Pharmacy, 20th Ed., ed. A. Gennaro, Lippincott Williams & Wilkins, 2000.
- the lyophilized solid composition may be stored for later reconstitution and administration.
- the solid composition is stored at a temperature of from 10° C. to 40° C., from 15° C. to 35° C., from 20° C. to 30° C., or about 25° C.
- the solid composition is sealed in a glass vial to protect the composition from moisture in the surrounding environment.
- a solid composition including caspofungin acetate, at least one amino acid and optionally one or more other substances may be administered to a patient by combining the composition with an aqueous carrier liquid to form an aqueous mixture, and administering the aqueous mixture into the patient by, for example, injection.
- the aqueous carrier liquid is a pharmaceutically acceptable carrier liquid.
- pharmaceutically acceptable carrier liquids include water and saline, such as sodium chloride injection, phosphate buffered saline (PBS), Ringers solution or lactated Ringers injection.
- the aqueous carrier liquid also may include fixed oils, fatty esters or polyols, particularly if the aqueous mixture for injection is a suspension.
- the aqueous carrier liquid also may include one or more other substances such as buffers, stabilizers, solubilizers, preservatives and antioxidants.
- the solid composition dissolves in the aqueous carrier liquid to form a solution.
- Presently preferred aqueous carrier liquids include sodium chloride injection, such as solutions containing 0.9%, 0.45% or 0.225% sodium chloride.
- Presently preferred aqueous carrier liquids include sterile water for injection.
- Presently preferred aqueous carrier liquids include bacteriostatic water for injection, which may include, for example, either 0.9% benzyl alcohol or a combination of methylparaben and propylparaben.
- Presently preferred aqueous carrier liquids include lactated Ringers injection.
- the aqueous carrier liquid does not include dextrose.
- the amount of aqueous carrier liquid may be sufficient to provide an initial aqueous mixture containing caspofungin acetate at a concentration of 5 milligrams per milliliter (mg/mL) or 7 mg/mL. At these concentrations, it is convenient to provide a 50 mg or 70 mg dose of caspofungin acetate to a patient, such as by dispensing 10 milliliters (mL) of the aqueous mixture into another aqueous liquid to form a final aqueous mixture.
- the presently recommended procedure includes combining the initial aqueous mixture with another aqueous liquid to form a final aqueous mixture, which is then administered to a patient.
- the amount of aqueous carrier liquid may be sufficient to provide a final aqueous mixture containing caspofungin acetate at a concentration of at most 0.5 mg/mL.
- Presently preferred concentrations of caspofungin acetate in a final aqueous mixture for administration to a patient are from 0.05 to 0.5 mg/mL, from 0.1 to 0.4 mg/mL, and from 0.15 to 0.3 mg/mL.
- Presently preferred concentrations of caspofungin acetate in a final aqueous mixture for administration to a patient include 0.19 mg/mL and 0.27 mg/mL.
- An aqueous mixture formed from the solid composition may be administered to provide an initial dose of 50-70 mg of caspofungin acetate to a patient.
- An aqueous mixture formed from the solid composition may be administered to provide a daily dose of 35-70 mg of caspofungin acetate to a patient. Doses outside of these ranges also may be administered.
- an initial dose includes 70 mg caspofungin acetate, and subsequent daily doses include 50 mg/mL caspofungin acetate.
- caspofungin acetate Daily doses of 70 mg/mL caspofungin acetate may be advisable under certain conditions, such as an insufficient response by the fungal infection and co-administration with other drugs that induce drug clearance (such as rifampin, nevirapine, efavirenz, carbamazepine, dexamethasone and phenytoin). Daily doses below 50 mg/mL of caspofungin acetate may be advisable under certain conditions, such as for pediatric patients or patients having moderate hepatic impairment.
- drugs that induce drug clearance such as rifampin, nevirapine, efavirenz, carbamazepine, dexamethasone and phenytoin.
- Daily doses below 50 mg/mL of caspofungin acetate may be advisable under certain conditions, such as for pediatric patients or patients having moderate hepatic impairment.
- group means a linked collection of atoms or a single atom within a molecular entity, where a molecular entity is any constitutionally or isotopically distinct atom, molecule, ion, ion pair, radical, radical ion, complex, conformer etc., identifiable as a separately distinguishable entity.
- amino acid means a molecular entity that includes at least one carboxylic acid group [—C( ⁇ O)OH] and at least one primary or secondary amine group [—NH 2 or —RNH, where —R is a molecular entity other than —H], but lacking a secondary amide group [—C( ⁇ O)—NH—].
- mass ratio of two substances means the mass of one substance (S1) relative to the mass of the other substance (S2), where both masses have identical units, expressed as S1:S2.
- lyophilizing means removing from a solution or an emulsion one or more substances having the lowest boiling points by freezing the solution or emulsion and applying a vacuum to the frozen mixture.
- solid means a substance that is not a liquid or a gas.
- a solid substance may have one of a variety of forms, including a monolithic solid, a powder, a gel or a paste.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A caspofungin composition includes caspofungin acetate and at least one amino acid, where the composition is a solid. The solid composition may be made by forming a liquid mixture including a solvent, caspofungin acetate and the amino acid(s), and lyophilizing the liquid mixture.
Description
- This application is a continuation of U.S. Nonprovisional application Ser. No. 13/724,266, filed Dec. 21, 2012, entitled “Caspofungin Acetate Formulations”, which claims the benefit of U.S. Provisional Application No. 61/728,406 entitled “Caspofungin Acetate Formulations” filed Nov. 20, 2012, both of which are incorporated by reference in the entirety.
- A variety of fungal infections can occur in patients due to pathogenic Candida or Aspergillus fungus species. Examples of such fungal infections include candidemia, candidiasis (including esophageal infections, abdominal infections, pleural space infections and peritoneal infections), and invasive aspergillosis. Early antifungal agents typically attacked the inner cell membrane of the invasive fungus. These early agents had a variety of drawbacks, however, including toxic side effects, drug-drug interactions, variations in efficacy between patients, and fungal resistance.
- A more recent family of antifungal agents is the echniocandins, which treat fungal infections through a different mechanism—inhibition of the enzyme that forms β-(1,3)-D-glucan, an essential component of the fungal outer cell wall. Since β-(1,3)-D-glucan does not occur naturally in the cell walls of mammals, the action of echinocandins is unlikely to be harmful to the cells of an infected patient. Due to the difference in their mechanism of action relative to earlier agents, echinocandins have not experienced wide resistance by target fungi.
- Caspofungin acetate was the first of the echinocandins to be approved in the U.S. for use as an antifungal agent. The full name for caspofungin acetate is reported as 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine] pneumocandin B0 diacetate (salt), and a representative chemical structure of caspofungin acetate is shown in
FIG. 1 . An approved treatment regimen for adults includes an initial administration of 70 milligrams (mg) caspofungin acetate, followed by daily administration of 50 mg caspofungin acetate, where each administration is performed through intravenous infusion over 1 hour. - As caspofungin acetate has poor oral bioavailability, it typically has been provided to medical personnel as a lyophilized solid, which is then reconstituted before intravenous administration to a patient. In one example, a formulation of caspofungin acetate that is commercially available at present is sold under the CANCIDAS® trademark. CANCIDAS® for Injection (Merck & Co, Inc.; Whitehouse Station, N.J., USA) is currently available as a lyophilized powder. CANCIDAS® is available in vials containing either 54.6 mg or 75.6 mg of caspofungin acetate, in combination with sucrose and mannitol, and including acetic acid and sodium hydroxide as pH modifiers. CANCIDAS® is reconstituted for administration by combining the lyophilized powder with 10.8 milliliters (mL) of a reconstitution liquid (such as 0.9% sodium chloride), to provide a solution having a caspofungin acetate concentration of either 7 milligrams per milliliter (mg/mL) or 5 mg/mL. This reconstituted liquid typically is diluted with an infusion liquid prior to administration.
- One challenge associated with the commercially available formulation of caspofungin acetate is its instability, including its instability at ambient temperatures. Degradation products of caspofungin acetate at room temperature (˜25° C.) include various dimers of caspofungin, as well as other substances. Current protocols require caspofungin acetate to be stored at −70° C. (±10° C.), and require the lyophilized CANCIDAS® formulation to be stored at temperatures of 2-8° C. A reconstituted liquid formed from the CANCIDAS® formulation must be diluted within one hour, and then either administered within 24 hours or stored at 2-8° C. for up to 48 hours. These temperature and time constraints present potential difficulties for effective administration of caspofungin acetate, both in medical professional settings and in outpatient settings. See, for example, Tsiouris, Maria et al. “Stability and compatibility of reconstituted caspofungin in select elastomeric infusion devices”, International Journal of Pharmaceutical Compounding (2010), 14(5), 436-439.
- Various reformulations have been reported to improve the stability of caspofungin. The use of the acetate salt form of caspofungin was an initial effort at improving the stability of caspofungin, as earlier versions of caspofungin formulations used the tartrate salt instead. Thus, the CANCIDAS® formulation, which includes caspofungin in its acetate salt form, has improved stability relative to formulations of caspofungin tartrate. See U.S. Pat. No. 5,952,300, column 2, lines 22-56 and column 8, lines 11-67.
- In another example, the pH modifiers acetic acid and sodium hydroxide were eliminated from the CANCIDAS® formulation, and the resulting formulations had improved stability at ambient temperatures. Lyophilized formulations were more stable with respect to caspofungin at 25° C. for 12 weeks, and reconstituted solutions of the formulations were more stable with respect to the caspofungin at 25° C. for 2 days. See US 2009/0170753, paragraphs [0080], [0204]-[0207] and [0214]-[0217].
- In another example, the sucrose and mannitol in the CANCIDAS® formulation were replaced with a non-reducing sugar such as trehalose, and the resulting formulations had improved stability at ambient temperatures. Lyophilized formulations containing trehalose more were stable with respect to caspofungin at 30° C. for up to 72 weeks, and at 40° C. for up to 24 weeks. See US 2010/0137197, paragraphs [0114]-[0119].
- It is desirable to have caspofungin acetate formulations that can be stored as lyophilized solids without the need for control of the surrounding temperature. For example, it is desirable for a lyophilized formulation of caspofungin acetate to be stable at temperatures of 25° C. or higher for a period of from 6 months to 2 years. Preferably such stabilized formulations would be convenient to prepare, store, reconstitute and administer.
- In one aspect, the invention provides a composition including caspofungin acetate and at least one amino acid, where the composition is a solid.
- In another aspect of the invention, there is a composition including from 50 to 70 mg caspofungin acetate, and arginine. The mass ratio of arginine to caspofungin acetate is from 2:5 to 3:1, and the composition is a solid.
- In another aspect of the invention, there is a composition, formed by a method including forming a liquid mixture that includes a solvent, caspofungin acetate and at least one amino acid, and lyophilizing the liquid mixture to form a solid composition.
- The invention can be better understood with reference to the following drawings and description. The components in the figures are not necessarily to scale and are not intended to accurately represent molecules or their interactions, emphasis instead being placed upon illustrating the principles of the invention.
-
FIG. 1 depicts a chemical structure of caspofungin acetate. -
FIGS. 2A and 2B depict chemical structures of examples of amino acids. - Lyophilized formulations that include caspofungin acetate and an amino acid can protect caspofungin acetate from degradation. These formulations may be stored at room temperature for up to two years, and thus may not require storage in a refrigerator or freezer prior to use. Reconstitution of the lyophilized formulations with a carrier liquid can yield an injectable liquid that may be used to administer caspofungin acetate.
- A composition may include caspofungin acetate, at least one amino acid and optionally one or more other substances, where the composition is a solid. The solid composition may be prepared by forming a liquid mixture including a solvent, caspofungin acetate and at least one amino acid, and then lyophilizing the mixture. The resulting solid composition may be used in administering caspofungin acetate to a patient by combining the composition with an aqueous carrier to form a solution or emulsion, which, for example, can be injected into a patient.
- Caspofungin acetate is a salt of one equivalent of caspofungin and two equivalents of acetic acid, providing an empirical formula of C52H88N10O15.2C2H4O2, and a formula weight of 1,213.42 grams per mole. The chemical structure shown in
FIG. 1 represents caspofungin acetate in its associated form. Caspofungin acetate may dissociate from one or both of its equivalents of acetic acid in the presence of a solvent; however, the salt still includes both the cyclic caspofungin and the acetic acid species. Thus, the term “caspofungin acetate” includes both an associated combination of caspofungin and acetic acid, as well as caspofungin and acetic acid in a dissociated state, such as may occur when the salt is combined with a solvent. - Caspofungin acetate does not include salts of caspofungin with substances other than acetic acid. For example, it has been reported that caspofungin can form pharmaceutically acceptable salts with substances including cations such as sodium, potassium, aluminum, calcium, lithium, magnesium and zinc; acids such as hydrochloric, hydrobromic, phosphoric, sulfuric, maleic, citric, tartaric, succinic, oxalic, malic, glutamic, lactic, propionic and pamoic acids; and bases such as ammonia, ethylenediamine, N-methyl-glutamine, lysine, arginine, ornithine, choline, N,N′-dibenzylethylene-diamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)aminomethane and tetramethyl-ammonium hydroxide. See U.S. Pat. No. 5,378,804 at column 1, line 67—column 2, line 5; U.S. Pat. No. 5,936,062 at column 2, lines 47-67; and US 2009/0170753 at paragraphs 35-36. These alternative salts, however, do not include acetic acid species, and thus are not included in the term “caspofungin acetate”.
- A solid composition that includes caspofungin acetate and an amino acid may include an amount of caspofungin acetate that is sufficient for a single initial dose of caspofungin acetate, or an amount sufficient for a daily maintenance dose of caspofungin acetate. A solid composition that includes caspofungin acetate and an amino acid may include an amount of caspofungin acetate that is sufficient for two or more initial doses of caspofungin acetate, or an amount sufficient for two or more daily maintenance doses of caspofungin acetate. The amount of caspofungin acetate in the composition may be a different therapeutic amount. For example, the amount of caspofungin acetate in the composition may be an amount sufficient for half of a single initial dose, or for half of a daily maintenance dose.
- In one example, a solid composition that includes caspofungin acetate and an amino acid may include from 10 to 150 milligrams (mg) caspofungin acetate. Preferably the composition includes from 25 to 100 mg caspofungin acetate, or from 50 to 70 mg caspofungin acetate. Presently preferred amounts of caspofungin acetate in the composition include about 50 mg and about 70 mg.
- A solid composition that includes caspofungin acetate and an amino acid includes one or more amino acids, which are compounds containing at least one carboxylic acid group [—C(═O)OH] and at least one primary or secondary amine group [—NH2 or —RNH, where —R is a molecular entity other than —H], but lacking a secondary amide group [—C(═O)—NH—].
FIG. 2 depicts chemical structures of examples of amino acids, includingalanine 202, 4-aminobutanoic acid 204, 3-aminopentanoic acid 206, 5-aminopentanoic acid 208, 6-aminohexanoic acid 210, 8-aminooctanoic acid 212,arginine 214,aspartic acid 216,asparagine 218,cysteine 220,glutamic acid 222,glutamine 224,glycine 226,histidine 228,isoleucine 230,leucine 232,lysine 234,methionine 236,methyl lysine 238,ornithine 240,phenylalanine 242,proline 244,serine 246,threonine 248,tryptophan 250,tyrosine 252 andvaline 254. Other amino acids, including isomers and substituted derivatives of the amino acids depicted inFIG. 2 , may be present in the composition. - Presently preferred amino acids for use in the solid compositions that include caspofungin acetate and at least one amino acid include 6-aminohexanoic acid 210,
arginine 214,asparagine 218,glycine 226,lysine 234,methyl lysine 238, andornithine 240. A solid composition that includes caspofungin acetate and an amino acid may include one or more amino acids that contain at least two primary or secondary amine groups. Examples of amino acids containing at least two primary or secondary amine groups includearginine 214,asparagine 218,lysine 234,methyl lysine 238, andornithine 240. - Surprisingly, it has been discovered that a solid composition including caspofungin acetate and an amino acid may be more stable than a solid composition including caspofungin acetate, mannitol and sucrose, such as the CANCIDAS® formulation (Merck & Co, Inc.). It is presently believed that solid compositions that include caspofungin acetate and an amino acid may be able to protect caspofungin acetate from degradation for a year or longer at room temperature (−25° C.), and for 6 months or longer at elevated temperatures.
- The amino acids arginine, asparagine and glycine can stabilize caspofungin acetate in solid compositions. Table 1 lists the results of stability analyses of lyophilized compositions of caspofungin acetate with
arginine 214,asparagine 218 andglycine 226, and for a conventional lyophilized composition of caspofungin acetate with mannitol and sucrose. For each solid composition listed in Table 1 that included an amino acid, 50 mg caspofungin acetate was combined with the listed amino acid and with water for injection (USP), and the pH was adjusted to about 6.0. The aqueous mixtures were then lyophilized to provide solid powders. Samples of each solid composition were sealed in vials at temperatures of 5° C., 25° C. or 40° C. The stability of the caspofungin acetate in the compositions over time at each temperature was determined by analyzing samples by High Pressure Liquid Chromatography (HPLC) and then calculating the total amount of relevant impurities of caspofungin detected in each HPLC analysis by peak area percent. The HPLC analysis was performed using a reversed phase HPLC having a variable wavelength UV/VIS detector and a C-18 column (2.7 micron, 150×4.6 mm ID). The liquid sample was passed through the HPLC using gradient elution at a flow rate of 1.0 mL/min and a temperature of 25° C. The impurities were detected using UV-detection at 225 nm, where the limit of quantification was <0.05%. Table 1 lists the percent total impurities measured for the lyophilized compositions. -
TABLE 1 Stability of Caspofungin Acetate Compositions FRESENIUS KABI USA LLC CONT-CASPOFUNGIN ACETATE FORMULATIONS JONATHAN M. BLANCHARD DRAFT INTERNAL Mannitol + Glycine Arginine Asparagine Sucrose* Mass Ratio Amino Acid:Caspofungin Acetate: 1:1 1:1 2:1 2:5 3:5 — Moisture content (%): Time Temperature 0.50 0.54 1.24 0.87 1.45 — (days) (° C.) Total Impurities (%) 4 5 1.61 0.60 — — 1.05 — 7 1.57 0.65 0.62 0.80 1.05 — 14 1.62 0.67 0.58 1.02 1.09 — 29 1.98 — 0.61 1.28 1.48 — 7 25 4.78 0.69 0.65 1.85 2.64 2.06 14 6.19 0.67 0.62 1.87 4.48 — 29 7.44 0.73 0.65 3.41 4.75 2.09 7 40 13.77 1.10 0.76 5.77 7.36 6.34 14 17.98 1.32 0.82 7.87 11.91 — 29 21.30 1.62 0.91 13.66 13.14 23.65 56 — 2.23 1.37 — — — *Conventional formulation; 1.93% total impurities at time = 0 days - The solid composition having a mass ratio of
arginine 214 to caspofungin acetate of 2:1 had the lowest level of impurities of the compositions listed in Table 1, from the initial days of the analysis and up to 56 days at 40° C. When stored at 5° C., 25° C. (room temperature), and 40° C. for 29 days, the impurity levels for this composition were only 0.61%, 0.65% and 0.91% respectively. - This 2:1 arginine composition was more stable than the conventional mannitol and sucrose composition at each time and temperature for which comparative results are listed. When stored at 25° C. for 7 days, the level of impurities in the solid composition having a mass ratio of arginine to caspofungin acetate of 2:1 was 68% less than the level of impurities in the conventional mannitol and sucrose composition [68%=100%×(2.06%−0.65%)/2.06%]. When stored at 25° C. for 29 days, the level of impurities in the solid composition having a mass ratio of arginine to caspofungin acetate of 2:1 was 69% less than the level of impurities in the conventional mannitol and sucrose composition [69%=100%×(2.09%−0.65%)/2.09%]. When stored at 40° C. for 7 days, the level of impurities in the solid composition having a mass ratio of arginine to caspofungin acetate of 2:1 was 88% less than the level of impurities in the conventional mannitol and sucrose composition [88%=100%×(6.34%−0.76%)/6.34%]. When stored at 40° C. for 29 days, the level of impurities in the solid composition having a mass ratio of arginine to caspofungin acetate of 2:1 was 96% less than the level of impurities in the conventional mannitol and sucrose composition [96%=100%×(23.65%−0.91%)/23.65%].
- When subjected to extended storage for 8 weeks (56 days) at an elevated temperature of 40° C., this 2:1 arginine composition maintained a total impurity level of 1.37%, which is acceptable under the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Based on this acceptable stability under these accelerated aging conditions, it is presently believed that a solid composition including caspofungin acetate and arginine in a 2:1 mass ratio of amino acid to caspofungin acetate will be stable for up to 2 years at room temperature, and will be stable for 6 months or longer at 40° C.
- The effect of
arginine 214 on the stability of caspofungin acetate in a solid composition appeared to be related to the relative amount of amino acid in the composition. The solid composition having a mass ratio of arginine to caspofungin acetate of 1:1 had a higher level of impurities than did the solid composition having a mass ratio of arginine to caspofungin acetate of 2:1, at each time and temperature for which comparative results are listed. - Despite this decrease in stability, the composition having the lower mass ratio of arginine to caspofungin acetate of 1:1 was still more stable than the conventional mannitol and sucrose composition at each temperature for which comparative results are listed. When stored at 25° C. for 7 days, the level of impurities in the solid composition having a mass ratio of arginine to caspofungin acetate of 1:1 was 67% less than the level of impurities in the conventional mannitol and sucrose composition [67%=100%×(2.06%−0.69%)/2.06%]. When stored at 25° C. for 29 days, the level of impurities in the solid composition having a mass ratio of arginine to caspofungin acetate of 1:1 was 65% less than the level of impurities in the conventional mannitol and sucrose composition [65%=100%×(2.09%−0.73%)/2.09%]. When stored at 40° C. for 7 days, the level of impurities in the solid composition having a mass ratio of arginine to caspofungin acetate of 1:1 was 83% less than the level of impurities in the conventional mannitol and sucrose composition [83%=100%×(6.34%−1.10%)/6.34%]. When stored at 40° C. for 29 days, the level of impurities in the solid composition having a mass ratio of arginine to caspofungin acetate of 1:1 was 93% less than the level of impurities in the conventional mannitol and sucrose composition [93%=100%×(23.65%−1.62%)/23.65%].
- The stabilizing effect of
asparagine 218 with regard to caspofungin acetate in a solid composition was less than the stabilizing effect of arginine. The solid compositions having mass ratios of asparagine to caspofungin acetate of 2:5 or 3:5 had higher levels of impurities than did the solid compositions having a mass ratio of arginine to caspofungin acetate of 2:1 or 1:1, at each time and temperature for which comparative results are listed. Compositions having a mass ratio of arginine to caspofungin acetate greater than 3:5 were not analyzed due to the lower aqueous solubility of asparagine in comparison to arginine. Despite this decrease in stability relative to compositions containing arginine, the stability of caspofungin acetate in compositions containing asparagine was comparable to that of the conventional mannitol and sucrose composition. Moreover, when stored at 40° C. for 29 days, the level of impurities in the solid compositions having mass ratios of asparagine to caspofungin acetate of 2:5 or 3:5 were 42-44% less than the level of impurities in the conventional mannitol and sucrose composition [(42%=100%×(23.65%−13.66%)/23.65%); (44%=100%×(23.65%−13.14%)/23.65%)]. - The stabilizing effect of
glycine 226 with regard to caspofungin acetate in a solid composition was less than the stabilizing effects of either arginine or asparagine. The solid composition having a mass ratio of glycine to caspofungin acetate of 1:1 had higher levels of impurities than did the solid compositions containing arginine or asparagine, at each time and temperature for which comparative results are listed. As noted in Tables 2 and 4 below, the mass ratio of glycine to caspofungin acetate could be higher than 1:1, such as 2:1 or 3:1. - Despite this decrease in stability relative to compositions containing arginine, the compositions of caspofungin acetate with glycine were still more stable overall than the conventional mannitol and sucrose composition when stored for 29 days at 40° C. When stored at 40° C. for 29 days, the level of impurities in the solid composition having a mass ratio of glycine to caspofungin acetate of 1:1 was 10% less than the level of impurities in the conventional mannitol and sucrose composition [10%=100%×(23.65%−21.30%)/23.65%].
- A variety of amino acids other than arginine, asparagine and glycine also can stabilize caspofungin acetate in solid compositions. Table 2 lists the results of stability analyses of lyophilized compositions of caspofungin acetate with the amino acids 6-aminohexanoic acid 210,
arginine 214,glycine 226,lysine 234,methyl lysine 238 andornithine 240. For each solid composition listed in Table 2, 50 mg caspofungin acetate was combined with the listed amino acid and with water for injection (USP), and the pH was adjusted. The aqueous mixtures were then lyophilized to provide solid powders. Samples of each solid composition were sealed in vials at temperatures of 25° C., 40° C. or 55° C. The stability of the caspofungin acetate in the compositions over time at each temperature was determined by analyzing samples by HPLC and then calculating the total amount of relevant impurities detected in each HPLC analysis by peak area percent, as described above with regard to the results of Table 1. Table 2 lists the percent total impurities measured for the lyophilized compositions. -
TABLE 2 Caspofungin Acetate (CA) Compositions Containing Amino Acids (AA) Amino acid (AA): 6-amino- methyl Arginine Glycine Ornithine Lysine hexanoic acid lysine Mass Ratio (AA:CA): 1:1 3:1 2:1 2:1 2:1 2:1 pH*: 6.55 7.21 6.46 6.66 6.65 6.36 Moisture content (%): Time Temperature 0.67 1.36 0.56 0.64 0.64 0.46 (weeks) (° C.) Total Impurities (%) 0 — 0.78 1.53 1.14 0.84 0.86 0.68 2 25 — 9.70 5.01 2.72 2.66 0.92 4 — 10.55 4.01 3.13 3.97 0.94 8 — — — — — 1.28 2 40 1.53 20.15 8.14 6.07 9.13 4.18 4 2.23 28.88 12.80 8.09 13.80 5.87 8 2.61 — — — — — 12 2.56 — — — — — 2 55 2.87 44.70 18.51 16.65 29.82 33.38 4 4.42 — — — — — *pH of liquid when reconstituted in water for injection. - Of the solid compositions listed in Table 2, the composition having a mass ratio of
arginine 214 to caspofungin acetate of 1:1 had the lowest level of impurities at elevated temperatures of 40° C. and 55° C., maintaining total impurity levels below 5% for the times and temperatures listed. The compositions containing 6-aminohexanoic acid 210,lysine 234,methyl lysine 238 orornithine 240 were less stable than the arginine composition, having total impurity levels of 5.87%-13.80% at an elevated temperature of 40° C. for 4 weeks, and total impurity levels of 16.65%-33.38% at an elevated temperature of 55° C. for 2 weeks. Thecomposition containing glycine 226 was the least stable of the amino acid compositions, having a total impurity level of 28.88% at an elevated temperature of 40° C. for 4 weeks, and a total impurity level of 44.70% at an elevated temperature of 55° C. for 2 weeks. - Arginine can be used in different amounts relative to the amount of caspofungin acetate in solid compositions. Table 3 lists the results of stability analyses of lyophilized compositions of caspofungin acetate having mass ratios of
arginine 214 to caspofungin acetate of 1:1 or 2:1. For each solid composition listed in Table 3, 50 mg caspofungin acetate was combined with the listed amino acid and with water for injection (USP), and the pH was adjusted. The aqueous mixtures were then lyophilized to provide solid powders. Samples of each solid composition were sealed in vials at temperatures of 25° C., 40° C. or 55° C. The stability of the caspofungin acetate in the compositions over time at each temperature was determined by analyzing samples by HPLC and then calculating the total amount of relevant impurities detected in each HPLC analysis by peak area percent, as described above with regard to the results of Table 1. Table 3 lists the percent total impurities measured for the lyophilized compositions. -
TABLE 3 Caspofungin Acetate (CA) Compositions Containing Amino Acids (AA) Amino acid (AA): Arginine Mass Ratio (AA:CA): 1:1 2:1 2:1 2:1 pH*: 6.55 5.77 6.74 7.46 Moisture content (%): 0.67 — — — Time Temperature (weeks) (° C.) Total Impurities (%) 0 — 0.78 1.25 1.28 1.50 12 25 — 1.53 1.63 1.68 2 40 1.53 — — — 4 2.23 1.91 2.03 2.12 8 2.61 2.73 2.42 2.52 12 2.56 2.84 2.69 2.77 2 55 2.87 3.82 3.96 4.08 4 4.42 4.81 4.91 5.39 *pH of liquid when reconstituted in water for injection. - The solid compositions having mass ratios of
arginine 214 to caspofungin acetate of 1:1 or 2:1 listed in Table 3 had good stability of the caspofungin acetate. When stored at 40° C. for up to 12 weeks, each of the listed compositions maintained total impurity levels below 3%. When stored at 55° C., the composition having an alkaline pH upon reconstitution had slightly less stability of the caspofungin acetate than did the compositions having acidic pH's. Each of the listed compositions, however, maintained total impurity levels below 5.5% when stored at 55° C. for up to 4 weeks. - The stabilization of caspofungin acetate by amino acids is surprising and unexpected, as shown by comparing the stabilities of solid compositions of caspofungin acetate in combination with a typical lyophilization stabilizing agent and/or glycine. Solid compositions of caspofungin acetate containing hydroxyethyl starch (HES) were less stable than were solid compositions of caspofungin acetate containing glycine. As HES is a typical lyophilization stabilizing agent, the improvement in caspofungin acetate stabilization that occurs when HES is replaced with glycine is not due to a simple replacement of one known stabilizing agent with another stabilizing agent. Moreover, since glycine was the least effective stabilizer of the amino acids listed in Tables 1 and 2 above, the improvement in stabilization achieved by replacing the HES with an amino acid is not a result of optimization of the amino acid composition.
- Table 4 lists the results of stability analyses of lyophilized compositions of caspofungin acetate with HES and/or glycine. For each formulation listed in Table 4, 50 mg caspofungin acetate was combined with the listed excipient(s) and with water for injection (USP), and the pH was adjusted to about 6.0. The aqueous mixtures were then lyophilized to provide solid powders. Samples of each formulation were sealed in vials at temperatures of 5° C., 25° C. or 40° C. The stability of the caspofungin acetate in the formulations over time at each temperature was determined by analyzing samples by HPLC and then calculating the total amount of relevant impurities detected in each HPLC analysis by peak area percent, as described above with regard to the results of Table 1. Table 4 lists the percent total impurities for lyophilized formulations of caspofungin acetate with the excipients HES and/or glycine.
-
TABLE 4 Stability of Caspofungin Acetate Compositions Containing HES and/or Glycine Excipient: HES + Glycine HES (1:1) Glycine Mass Ratio (Excipient:Caspofungin Acetate): 2:1 2:1 2:1 1:1 1:1 Moisture content (%): Time Temperature 0.62 0.39 0.49 0.53 1.29 (days) (° C.) Total Impurities (%) 0 — 2.10 1.25 0.81 0.90 1.02 7 5 2.90 1.57 0.90 1.08 1.12 14 2.85 1.61 0.85 1.09 — 28 3.40 1.75 0.84 1.09 1.31 7 25 6.48 3.39 1.48 2.09 2.58 14 8.79 4.30 1.90 2.67 3.59 28 10.15 5.89 2.68 3.76 5.31 7 40 18.04 12.21 5.10 7.87 8.08 14 24.71 16.98 7.59 12.52 13.17 28 — — 9.40 13.76 — - The HES formulation (mass ratio of HES to caspofungin acetate of 2:1) had a high level of impurities even at the beginning of the analysis. The 2.10% impurity level at the beginning of the analysis rose to 3.40%, 10.15% and 24.71% after storage for 28 days at 5° C., for 28 days at 25° C. (room temperature), and for 14 days at 40° C., respectively.
- Substituting half of the HES excipient with glycine reduced the amount of impurities in the formulation relative to the amounts in the 2:1 HES formulation. Substituting half of the HES excipient with glycine reduced the amount of impurities at the beginning of the analysis by 41% [40.5%=100%×(2.10%−1.25%)/2.10%], reduced the amount of impurities after storage for 28 days at 5° C. by 49% [48.5%=100%×(3.40%−1.75%)/3.40%], reduced the amount of impurities after storage for 28 days at 25° C. by 42% [42.0%=100%×(10.15%−5.89%)/10.15%], and reduced the amount of impurities after storage for 14 days at 40° C. by 31% [31.3%=100%×(24.71%−16.98%)/24.71%].
- Substituting the remaining HES excipient with glycine further reduced the amount of impurities in the formulation. The formulations with glycine but without HES as an excipient (mass ratio of glycine to caspofungin acetate of 1:1 or 2:1), had impurity levels of approximately 1% or lower at the beginning of the analysis. Substituting the remaining HES excipient with glycine (mass ratio glycine to caspofungin acetate of 2:1) further reduced the amount of impurities at the beginning of the analysis by 35% [35.2%=100%×(1.25%−0.81%)/1.25%], further reduced the amount of impurities after storage for 28 days at 5° C. by 52% [52.0%=100%×(1.75%−0.84%)/1.75%], further reduced the amount of impurities after storage for 28 days at 25° C. by 55% [54.5%=100%×(5.89%−2.68%)/5.89%], and further reduced the amount of impurities after storage for 14 days at 40° C. by 55% [55.3%=100%×(16.98%−7.59%)/16.98%]. Overall, substituting the entire HES excipient with glycine reduced the amount of impurities at the beginning of the analysis by 61% [61.4%=100%×(2.10% - 0.81%) / 2.10%], reduced the amount of impurities after storage for 28 days at 5 ° C. by 75% [75.3% =100% x (3.40% -0.84%) / 3.40%], reduced the amount of impurities after storage for 28 days at 25 ° C. by 74% [73.6% =100% x (10.15% -2.68%) / 10.15%], and reduced the amount of impurities after storage for 14 days at 40 ° C. by 69% [69.3% =100% x (24.71% -7.59%) / 24.71%].
- The stabilization of caspofungin acetate due to removal of HES was observed even when the concentration of the amino acid was lower than the concentration of the HES. The formulation having a mass ratio glycine to caspofungin acetate of 1:1 and a moisture content of 0.53% corresponded to removing the HES excipient from the formulation having a mass ratio of HES to glycine to caspofungin acetate of 1:1:1. Thus, removal of the HES reduced the amount of impurities at the beginning of the analysis by 28% [28.0%=100%×(1.25%−0.90%)/1.25%], reduced the amount of impurities after storage for 28 days at 5° C. by 38% [37.7%=100%×(1.75%−1.09%)/1.75%], reduced the amount of impurities after storage for 28 days at 25° C. by 36% [36.2%=100%×(5.89%−3.76%)/5.89%], and reduced the amount of impurities after storage for 14 days at 40° C. by 26% [26.3%=100%×(16.98%−12.52%)/16.98%].
- Overall, switching the formulation from a mass ratio of HES to caspofungin acetate of 2:1 to a mass ratio of glycine to caspofungin acetate of 1:1 (moisture content of 0.53%) reduced the amount of impurities at the beginning of the analysis by 57% [57.1%=100%×(2.10%−0.90%)/2.10%], reduced the amount of impurities after storage for 28 days at 5° C. by 68% [67.9%=100%×(3.40%−1.09%)/3.40%], reduced the amount of impurities after storage for 28 days at 25° C. by 63% [63.0%=100%×(10.15%−3.76%)/10.15%], and reduced the amount of impurities after storage for 14 days at 40° C. by 49% [49.3%=100%×(24.71%−12.52%)/24.71%]. Thus, although the caspofungin acetate was less stable in a formulation having a glycine to caspofungin acetate mass ratio of 1:1 than in a formulation having a glycine to caspofungin acetate mass ratio of 2:1, the caspofungin acetate was still more stable when combined with glycine as the only excipient than when HES was the only excipient.
- The stabilization of lyophilized caspofungin acetate in combination with an amino acid may be affected by the water content of the lyophilized solid. Referring to Table 3, an approximately 2-fold increase in water content (from 0.53% to 1.29%) of the lyophilized formulation containing a 1:1 mass ratio of glycine to caspofungin acetate resulted in a decrease in caspofungin acetate stability. Even this decreased stability, however, was an improvement over the formulations that included HES as an excipient but that had a lower moisture content. Thus, even when combined with a moisture increase of 231% [230.8%=100%×(1.29%−0.39%)/0.39%], removing the HES excipient from the formulation having a mass ratio of HES to glycine to caspofungin acetate of 1:1:1 reduced the amount of impurities at the beginning of the analysis by 18% [18.4%=100%×(1.25%−1.02%)/1.25%], reduced the amount of impurities after storage for 28 days at 5° C. by 25% [25.1%=100%×(1.75%−1.31%)/1.75%], reduced the amount of impurities after storage for 28 days at 25° C. by 10% [9.8%=100%×(5.89%−5.31%)/5.89%], and reduced the amount of impurities after storage for 14 days at 40° C. by 22% [22.4%=100%×(16.98%−13.17%)/16.98%]. Overall, switching the formulation from a mass ratio of HES to caspofungin acetate of 2:1 to a mass ratio of glycine to caspofungin acetate of 1:1, even when combined with a moisture increase of 108% [108.1%=100%×(1.29%−0.62%)/0.62%], reduced the amount of impurities at the beginning of the analysis by 51% [51.4%=100%×(2.10%−1.02%)/2.10%], reduced the amount of impurities after storage for 28 days at 5° C. by 62% [61.5%=100%×(3.40%−1.31%)/3.40%], reduced the amount of impurities after storage for 28 days at 25° C. by 48% [47.7%=100%×(10.15%−5.31%)/10.15%], and reduced the amount of impurities after storage for 14 days at 40° C. by 47% [46.7%=100%×(24.71%−13.17%)/24.71%].
- The surprising and unexpected stabilization of caspofungin by amino acids may be used to prepare solid compositions including caspofungin acetate that are more stable than a conventional solid composition including caspofungin acetate, mannitol and sucrose. The surprising and unexpected stabilization of caspofungin by amino acids may be used to prepare solid compositions including caspofungin acetate that are able to protect caspofungin acetate from degradation for a year or longer at room temperature (−25° C.), and for 6 months or longer at elevated temperatures.
- A solid composition that includes caspofungin acetate and an amino acid may include an amount of the amino acid sufficient to stabilize the caspofungin acetate. Preferably the amount of the amino acid in the composition is at most an amount that will dissolve in a sample of aqueous liquid, such as a volume of aqueous liquid used for reconstitution of the solid composition.
- In one example, a solid composition that includes caspofungin acetate and an amino acid may include from 20 to 350 mg of the amino acid. For a solid composition that includes approximately 50 mg caspofungin acetate, the amount of amino acid in the composition preferably is from 20 to 250 mg, from 20 to 150 mg, from 20 to 100 mg, from 30 to 250 mg, from 30 to 150 mg, or from 30 to 100 mg. For a solid composition that includes approximately 70 mg caspofungin acetate, the amount of amino acid in the composition preferably is from 28 to 350 mg, from 28 to 210 mg, from 28 to 140 mg, from 42 to 350 mg, from 42 to 210 mg, or from 42 to 140 mg.
- A solid composition that includes caspofungin acetate and an amino acid may have a mass ratio of amino acid to caspofungin of at least 2:5, where the mass of amino acid in the ratio accounts for all amino acid species present in the solid composition. Preferably the mass ratio of amino acid to caspofungin acetate is at least 3:5, at least 1:1 or at least 2:1. Preferably the mass ratio of amino acid to caspofungin acetate is at most 3:1 or at most 2:1. Preferably the mass ratio of amino acid to caspofungin acetate is from 2:5 to 3:1, from 3:5 to 2:1, or from 1:1 to 3:1.
- A solid composition that includes caspofungin acetate and an amino acid may further include an acid and/or a base. The pH of a saturated solution of caspofungin acetate in water is about 6.6 (CANCIDAS® prescribing information, Merck Sharp & Dohme Corp., June, 2010, p. 14). The amount of the acid and/or base may be an amount sufficient to provide a pH in the range of 5 to 7 or of 6 to 7 when the composition is reconstituted in 10.8 mL of an aqueous liquid. Preferably the amount of the acid and/or base may be an amount sufficient to provide a pH in the range of 5 to 7 or of 6 to 7 when the composition is reconstituted in 10.8 mL of 0.9% aqueous sodium chloride (USP), sterile water for injection, or bacteriostatic water for injection containing either 0.9% benzyl alcohol or a combination of methylparaben and propylparaben. Presently preferred acids include hydrochloric acid. Presently preferred bases include sodium hydroxide.
- A solid composition that includes caspofungin acetate and an amino acid may further include one or more other substances. Non-limiting examples of other substances include bulking agents, carriers, diluents, fillers, salts, buffers, stabilizers, solubilizers, preservatives, antioxidants, and tonicity contributors. Substances that may be useful in formulating pharmaceutically acceptable compositions, and methods of forming such compositions, are described for example in Remington: The Science and Practice of Pharmacy, 20th Ed., ed. A. Gennaro, Lippincott Williams & Wilkins, 2000, and in Kibbe, “Handbook of Pharmaceutical Excipients,” 3rd Edition, 2000. Preferably the solid composition does not include dextrose, as caspofungin acetate is reportedly unstable when reconstituted in a liquid containing dextrose. See CANCIDAS® prescribing information, Merck Sharp & Dohme Corp., June, 2010, p. 3.
- A solid composition including caspofungin acetate, at least one amino acid and optionally one or more other substances may be prepared by forming a liquid mixture that includes a solvent, caspofungin acetate, amino acid(s) and optionally one or more other substances, and lyophilizing the liquid mixture. The lyophilizing may include freeze-drying the liquid mixture to provide a solid composition. The liquid mixture may include caspofungin acetate and an amino acid in the amounts described above. The liquid mixture may further include an acid, a base and/or one or more other substances, as described above.
- The liquid mixture may include from 0.1 to 5 mL solvent, from 10 to 150 mg caspofungin acetate, and from 20 to 350 mg amino acid. The liquid mixture may include from 0.5 to 2 mL solvent, from 25 to 100 mg caspofungin acetate, and from 20 to 350 mg amino acid. The liquid mixture may include from 0.75 to 1.5 mL solvent, from 50 to 70 mg caspofungin acetate, and from 20 to 350 mg amino acid. The mass ratio of amino acid to caspofungin acetate in the liquid mixture may be from 2:5 to 3:1, from 3:5 to 2:1, or from 1:1 to 3:1.
- The solvent, caspofungin acetate, amino acid, optional acid, optional base and one or more other optional substances may be combined in any order when forming the liquid mixture. For example, a liquid mixture may be formed by adding the caspofungin acetate and the amino acid(s) to a container including the solvent, and then adding the acid and/or base to achieve the desired pH in the liquid mixture. The liquid mixture preferably has a pH of from 6 to 7. A presently preferred pH of the liquid mixture is 6±1.
- The liquid mixture including the solvent, caspofungin acetate, amino acid, and any other optional ingredients may be lyophilized to form a solid composition, such as by subjecting the liquid mixture to freeze-drying. Freeze-drying of the liquid mixture may include maintaining the liquid mixture in an inert atmosphere, such as nitrogen or argon. Preferably the liquid mixture is placed in glass vials prior to lyophilization, and the amount of the liquid mixture in each vial is based on the amount of caspofungin acetate intended to be present in the final solid composition in the vial.
- In a typical lyophilization process, the temperature of the liquid mixture is lowered to a temperature at or below the solidification point of the liquid mixture. If the liquid mixture forms a glass when cooled, the solidification point is the glass transition temperature. If the liquid mixture forms crystals when cooled, the solidification point is the eutectic point. The solidified mixture is then dried under vacuum. Typically, the drying process includes a primary drying step in which the temperature of the solidified mixture is raised gradually while most of the water is removed from the mixture by the vacuum, and a secondary drying step in which the temperature of the solidified mixture is raised further while residual moisture is removed from the mixture by the vacuum. The temperature is kept at or below the desired storage temperature for the final solid composition. Lyophilization typically is complete within 48 hours, but may require additional time. The solid composition resulting from the lyophilization typically is sealed for later use. Details regarding the lyophilization process may be found, for example, in Remington: The Science and Practice of Pharmacy, 20th Ed., ed. A. Gennaro, Lippincott Williams & Wilkins, 2000.
- The lyophilized solid composition may be stored for later reconstitution and administration. Preferably the solid composition is stored at a temperature of from 10° C. to 40° C., from 15° C. to 35° C., from 20° C. to 30° C., or about 25° C. Preferably the solid composition is sealed in a glass vial to protect the composition from moisture in the surrounding environment.
- A solid composition including caspofungin acetate, at least one amino acid and optionally one or more other substances may be administered to a patient by combining the composition with an aqueous carrier liquid to form an aqueous mixture, and administering the aqueous mixture into the patient by, for example, injection. Preferably, the aqueous carrier liquid is a pharmaceutically acceptable carrier liquid. Non-limiting examples of pharmaceutically acceptable carrier liquids include water and saline, such as sodium chloride injection, phosphate buffered saline (PBS), Ringers solution or lactated Ringers injection. The aqueous carrier liquid also may include fixed oils, fatty esters or polyols, particularly if the aqueous mixture for injection is a suspension. The aqueous carrier liquid also may include one or more other substances such as buffers, stabilizers, solubilizers, preservatives and antioxidants. Preferably the solid composition dissolves in the aqueous carrier liquid to form a solution.
- Presently preferred aqueous carrier liquids include sodium chloride injection, such as solutions containing 0.9%, 0.45% or 0.225% sodium chloride. Presently preferred aqueous carrier liquids include sterile water for injection. Presently preferred aqueous carrier liquids include bacteriostatic water for injection, which may include, for example, either 0.9% benzyl alcohol or a combination of methylparaben and propylparaben. Presently preferred aqueous carrier liquids include lactated Ringers injection. Preferably the aqueous carrier liquid does not include dextrose.
- The amount of aqueous carrier liquid may be sufficient to provide an initial aqueous mixture containing caspofungin acetate at a concentration of 5 milligrams per milliliter (mg/mL) or 7 mg/mL. At these concentrations, it is convenient to provide a 50 mg or 70 mg dose of caspofungin acetate to a patient, such as by dispensing 10 milliliters (mL) of the aqueous mixture into another aqueous liquid to form a final aqueous mixture. While an initial aqueous mixture containing caspofungin acetate at a concentration of 5 or 7 mg/mL may be injected into a patient, the presently recommended procedure includes combining the initial aqueous mixture with another aqueous liquid to form a final aqueous mixture, which is then administered to a patient.
- The amount of aqueous carrier liquid may be sufficient to provide a final aqueous mixture containing caspofungin acetate at a concentration of at most 0.5 mg/mL. For example, 10 mL of an initial aqueous mixture containing 5 or 7 mg/mL caspofungin acetate may be combined with 250 mL of an aqueous carrier liquid to provide a final aqueous mixture containing 0.19 mg/mL or 0.27 mg/mL caspofungin acetate (0.192 mg/mL=50 mg/(250 mL+10 mL); 0.269 mg/mL=70 mg/(250 mL+10 mL)). Presently preferred concentrations of caspofungin acetate in a final aqueous mixture for administration to a patient are from 0.05 to 0.5 mg/mL, from 0.1 to 0.4 mg/mL, and from 0.15 to 0.3 mg/mL. Presently preferred concentrations of caspofungin acetate in a final aqueous mixture for administration to a patient include 0.19 mg/mL and 0.27 mg/mL.
- An aqueous mixture formed from the solid composition may be administered to provide an initial dose of 50-70 mg of caspofungin acetate to a patient. An aqueous mixture formed from the solid composition may be administered to provide a daily dose of 35-70 mg of caspofungin acetate to a patient. Doses outside of these ranges also may be administered. Typically, an initial dose includes 70 mg caspofungin acetate, and subsequent daily doses include 50 mg/mL caspofungin acetate. Daily doses of 70 mg/mL caspofungin acetate may be advisable under certain conditions, such as an insufficient response by the fungal infection and co-administration with other drugs that induce drug clearance (such as rifampin, nevirapine, efavirenz, carbamazepine, dexamethasone and phenytoin). Daily doses below 50 mg/mL of caspofungin acetate may be advisable under certain conditions, such as for pediatric patients or patients having moderate hepatic impairment.
- To provide a clear and more consistent understanding of the specification and claims of this application, the following definitions are provided.
- The term “group” means a linked collection of atoms or a single atom within a molecular entity, where a molecular entity is any constitutionally or isotopically distinct atom, molecule, ion, ion pair, radical, radical ion, complex, conformer etc., identifiable as a separately distinguishable entity.
- The term “amino acid” means a molecular entity that includes at least one carboxylic acid group [—C(═O)OH] and at least one primary or secondary amine group [—NH2 or —RNH, where —R is a molecular entity other than —H], but lacking a secondary amide group [—C(═O)—NH—].
- The term “mass ratio” of two substances means the mass of one substance (S1) relative to the mass of the other substance (S2), where both masses have identical units, expressed as S1:S2.
- The term “lyophilizing” means removing from a solution or an emulsion one or more substances having the lowest boiling points by freezing the solution or emulsion and applying a vacuum to the frozen mixture.
- The term “solid” means a substance that is not a liquid or a gas. A solid substance may have one of a variety of forms, including a monolithic solid, a powder, a gel or a paste.
- While various embodiments of the invention have been described, it will be apparent to those of ordinary skill in the art that other embodiments and implementations are possible within the scope of the invention. Accordingly, the invention is not to be restricted except in light of the attached claims and their equivalents.
Claims (40)
1. A composition, comprising:
caspofungin acetate, and
at least one an amino acid;
where the composition is a solid.
2. The composition of claim 1 , where the at least one amino acid comprises an amino acid having at least two primary or secondary amine groups.
3. The composition of claim 2 , where the at least one amino acid is an amino acid selected from the group consisting of arginine, asparagine, lysine, methyl lysine, and ornithine.
4. The composition of claim 1 , where the at least one amino acid is selected from the group consisting of alanine, 4-aminobutanoic acid, 3-aminopentanoic acid, 5-aminopentanoic acid, 6-aminohexanoic acid, 8-aminooctanoic acid, arginine, aspartic acid, asparagine, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, methyl lysine, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine.
5. The composition of claim 1 , where the at least one amino acid is selected from the group consisting of 6-aminohexanoic acid, arginine, asparagine, glycine, lysine, methyl lysine, and ornithine.
6. The composition of claim 1 , where the at least one amino acid comprises at least two amino acids.
7. The composition of claim 1 , comprising from 10 to 150 mg caspofungin acetate.
8. The composition of claim 1 , comprising from 25 to 100 mg caspofungin acetate.
9. The composition of claim 1 , comprising from 50 to 70 mg caspofungin acetate.
10. The composition of claim 1 , where the mass ratio of the at least one amino acid to caspofungin acetate is at least 3:5.
11. The composition of claim 1 , where the mass ratio of the at least one amino acid to caspofungin acetate is at least 1:1.
12. The composition of claim 1 , where the mass ratio of the at least one amino acid to caspofungin acetate is at least 2:1.
13. The composition of claim 1 , where the mass ratio of the at least one amino acid to caspofungin acetate is at most 3:1.
14. The composition of claim 1 , where the mass ratio of the at least one amino acid to caspofungin acetate is at most 2:1.
15. The composition of claim 1 , where the mass ratio of the at least one amino acid to caspofungin acetate is from 2:5 to 3:1.
16. The composition of claim 1 , where the mass ratio of the at least one amino acid to caspofungin acetate is from 3:5 to 2:1.
17. The composition of claim 1 , where the mass ratio of the at least one amino acid to caspofungin acetate is from 1:1 to 3:1.
18. A composition, formed by a method comprising:
forming a liquid mixture comprising
a solvent,
caspofungin acetate, and
at least one an amino acid; and
lyophilizing the liquid mixture to form a solid composition.
19. The composition of claim 18 , where the at least one amino acid is an amino acid having at least two primary or secondary amine groups.
20. The composition of claim 19 , where the at least one amino acid is an amino acid selected from the group consisting of arginine, asparagine, lysine, methyl lysine, and ornithine.
21. The composition of claim 18 , where the at least one amino acid is selected from the group consisting of alanine, 4-aminobutanoic acid, 3-aminopentanoic acid, 5-aminopentanoic acid, 6-aminohexanoic acid, 8-aminooctanoic acid, arginine, aspartic acid, asparagine, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, methyl lysine, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine.
22. The composition of claim 18 , where the at least one amino acid is selected from the group consisting of 6-aminohexanoic acid, arginine, asparagine, glycine, lysine, methyl lysine, and ornithine.
23. The composition of claim 18 , where the at least one amino acid comprises at least two amino acids.
24. The composition of claim 18 , comprising from 10 to 150 mg caspofungin acetate.
25. The composition of claim 18 , comprising from 25 to 100 mg caspofungin acetate.
26. The composition of claim 18 , comprising from 50 to 70 mg caspofungin acetate.
27. The composition of claim 18 , where the mass ratio of the at least one amino acid to caspofungin acetate is at least 3:5.
28. The composition of claim 18 , where the mass ratio of the at least one amino acid to caspofungin acetate is at least 1:1.
29. The composition of claim 18 , where the mass ratio of the at least one amino acid to caspofungin acetate is at least 2:1.
30. The composition of claim 18 , where the mass ratio of the at least one amino acid to caspofungin acetate is at most 3:1.
31. The composition of claim 18 , where the mass ratio of the at least one amino acid to caspofungin acetate is at most 2:1.
32. The composition of claim 18 , where the mass ratio of the at least one amino acid to caspofungin acetate is from 2:5 to 3:1.
33. The composition of claim 18 , where the mass ratio of the at least one amino acid to caspofungin acetate is from 3:5 to 2:1.
34. The composition of claim 18 , where the mass ratio of the at least one amino acid to caspofungin acetate is from 1:1 to 3:1.
35. The composition of claim 18 , where the mass ratio of the at least one amino acid to caspofungin acetate in the liquid mixture is at least 2:5.
36. The composition of claim 18 , where the mass ratio of the at least one amino acid to caspofungin acetate in the liquid mixture is at least 3:5.
37. The composition of claim 18 , where the mass ratio of the at least one amino acid to caspofungin acetate in the liquid mixture is at least 1:1.
38. A composition, comprising:
from 50 to 70 mg caspofungin acetate, and arginine;
where the mass ratio of arginine to caspofungin acetate is from 2:5 to 3:1, and the composition is solid.
39. The composition of claim 38 , where the mass ratio of arginine to caspofungin acetate is from 3:5 to 2:1.
40. The composition of claim 38 , where the mass ratio of arginine to caspofungin acetate is from 1:1 to 3:1.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/474,531 US20170296667A1 (en) | 2012-11-20 | 2017-03-30 | Caspofungin Acetate Formulations |
US15/947,453 US20190105392A1 (en) | 2012-11-20 | 2018-04-06 | Caspofungin Acetate Formulations |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261728406P | 2012-11-20 | 2012-11-20 | |
US13/724,266 US9636407B2 (en) | 2012-11-20 | 2012-12-21 | Caspofungin acetate formulations |
US15/474,531 US20170296667A1 (en) | 2012-11-20 | 2017-03-30 | Caspofungin Acetate Formulations |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/724,266 Continuation US9636407B2 (en) | 2012-11-20 | 2012-12-21 | Caspofungin acetate formulations |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/947,453 Continuation US20190105392A1 (en) | 2012-11-20 | 2018-04-06 | Caspofungin Acetate Formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170296667A1 true US20170296667A1 (en) | 2017-10-19 |
Family
ID=47505366
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/724,266 Active US9636407B2 (en) | 2012-11-20 | 2012-12-21 | Caspofungin acetate formulations |
US15/165,389 Abandoned US20160310597A1 (en) | 2012-11-20 | 2016-05-26 | Caspofungin Acetate Formulations |
US15/474,531 Abandoned US20170296667A1 (en) | 2012-11-20 | 2017-03-30 | Caspofungin Acetate Formulations |
US15/947,453 Abandoned US20190105392A1 (en) | 2012-11-20 | 2018-04-06 | Caspofungin Acetate Formulations |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/724,266 Active US9636407B2 (en) | 2012-11-20 | 2012-12-21 | Caspofungin acetate formulations |
US15/165,389 Abandoned US20160310597A1 (en) | 2012-11-20 | 2016-05-26 | Caspofungin Acetate Formulations |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/947,453 Abandoned US20190105392A1 (en) | 2012-11-20 | 2018-04-06 | Caspofungin Acetate Formulations |
Country Status (15)
Country | Link |
---|---|
US (4) | US9636407B2 (en) |
EP (1) | EP2922530B1 (en) |
CA (1) | CA2888625A1 (en) |
CY (1) | CY1120016T1 (en) |
DK (1) | DK2922530T3 (en) |
ES (1) | ES2607646T3 (en) |
HK (1) | HK1215668A1 (en) |
HR (1) | HRP20161703T1 (en) |
HU (1) | HUE032392T2 (en) |
LT (1) | LT2922530T (en) |
PL (1) | PL2922530T3 (en) |
PT (1) | PT2922530T (en) |
SI (1) | SI2922530T1 (en) |
SM (1) | SMT201600452B (en) |
WO (1) | WO2014081443A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2922530T1 (en) * | 2012-11-20 | 2017-04-26 | Fresenius Kabi Usa, Llc | Caspofungin acetate formulations |
WO2017185030A1 (en) * | 2016-04-22 | 2017-10-26 | Fresenius Kabi Usa, Llc | Caspofungin formulation with low impurities |
CA3128398A1 (en) | 2018-02-01 | 2019-08-08 | The Royal Institution For The Advancement Of Learning / Mcgill University | Formulations for improving the delivery of hydrophobic agents |
WO2019157453A1 (en) | 2018-02-12 | 2019-08-15 | Trilogy Therapeutics, Inc. | Caspofungin compositions for inhalation |
CN109758426B (en) * | 2019-01-24 | 2021-04-27 | 四川制药制剂有限公司 | Caspofungin acetate pharmaceutical composition for injection and preparation method thereof |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5378804A (en) * | 1993-03-16 | 1995-01-03 | Merck & Co., Inc. | Aza cyclohexapeptide compounds |
ES2181790T3 (en) | 1994-09-16 | 2003-03-01 | Merck & Co Inc | AZACICLOHEXAPEPTIDIC COMPOUNDS. |
US5516756A (en) | 1994-10-31 | 1996-05-14 | Merck & Co., Inc. | Aza cyclohexapeptide compounds |
US5552521A (en) | 1995-02-10 | 1996-09-03 | Merck & Co., Inc. | Process for preparing certain aza cyclohexapeptides |
US5952300A (en) * | 1996-04-19 | 1999-09-14 | Merck & Co., Inc. | Antifungal compositions |
US6069126A (en) | 1996-09-12 | 2000-05-30 | Merck & Co., Inc. | Antifungal combination therapy |
US5936062A (en) | 1997-06-12 | 1999-08-10 | Merck & Co., Inc. | Process for preparing certain aza cyclohexapeptides |
DE60034445T2 (en) | 1999-05-31 | 2008-01-03 | Mitsubishi Chemical Corp. | FREEZE-DRIED HGF PREPARATIONS |
ES2220724T3 (en) | 2000-01-20 | 2004-12-16 | Basilea Pharmaceutica Ag | COMPOSITIONS OF ADMINISTRABLE CYCLIC PEPTIDES VIA NASAL. |
US6803046B2 (en) | 2002-08-16 | 2004-10-12 | Bracco International B.V. | Sincalide formulations |
US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
BRPI0715113A2 (en) * | 2006-07-26 | 2013-06-04 | Sandoz Ag Sandoz Sa Sandoz Ltd | caspofungin formulation |
TW200826957A (en) | 2006-10-16 | 2008-07-01 | Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag | Purification processes for echinocandin-type compounds |
AU2008269140A1 (en) * | 2007-06-26 | 2008-12-31 | Merck Sharp & Dohme Corp. | Lyophilized anti-fungal composition |
US20110014676A1 (en) | 2007-06-29 | 2011-01-20 | Battelle Memorial Institute | Protein stabilization |
CA2722602A1 (en) | 2008-05-15 | 2009-11-19 | Baxter International Inc. | Stable pharmaceutical formulations |
US20090291996A1 (en) | 2008-05-21 | 2009-11-26 | Ferenc Korodi | Caspofungin free of caspofungin Co |
EP2240507A2 (en) | 2008-06-25 | 2010-10-20 | TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság | Processes for preparing high purity aza cyclohexapeptides |
US20090324635A1 (en) | 2008-06-25 | 2009-12-31 | Ferenc Korodi | Caspofungin free of caspofungin impurity A |
GB0817121D0 (en) | 2008-09-18 | 2008-10-29 | Univ St Andrews | Anti-fungal therapy |
TW201024322A (en) | 2008-12-31 | 2010-07-01 | Chunghwa Chemical Synthesis & Biotech Co Ltd | Preparation method for nitrogen containing heterocyclic hexapeptide with high conversion rate |
US9394340B2 (en) | 2009-03-24 | 2016-07-19 | Cadila Healthcare Limited | Purification process for lipopeptides |
CN102947327B (en) | 2010-03-29 | 2017-06-13 | 中化帝斯曼制药有限公司荷兰公司 | The purifying of Caspofungin intermediate |
MX2013003045A (en) * | 2010-09-20 | 2013-06-24 | Xellia Pharmaceuticals Aps | Caspofungin composition. |
EP2621941A1 (en) | 2010-09-28 | 2013-08-07 | DSM Sinochem Pharmaceuticals Netherlands B.V. | Method for isolating a cyclohexapeptide |
US20140005355A1 (en) | 2011-01-03 | 2014-01-02 | Biocon Limited | Process for preparation of caspofungin acetate and intermediates |
CN102166186A (en) | 2011-04-18 | 2011-08-31 | 深圳市健元医药科技有限公司 | More stable nitrogen heterocyclic peptide preparation |
CN102746384B (en) | 2011-04-22 | 2016-01-20 | 上海天伟生物制药有限公司 | A kind of highly purified Caspofungin or its salt and its production and use |
KR20140042805A (en) | 2011-04-28 | 2014-04-07 | 유니트리스 바이오파마 컴퍼니 리미티드 | Intermediate for synthesizing caspofungin and preparation method therefor |
SI2922530T1 (en) * | 2012-11-20 | 2017-04-26 | Fresenius Kabi Usa, Llc | Caspofungin acetate formulations |
US9828411B2 (en) | 2013-05-02 | 2017-11-28 | Dsm Sinochem Pharmaceuticals Netherlands B.V. | Method for isolating caspofungin |
US9556233B2 (en) | 2013-09-11 | 2017-01-31 | Dsm Sinochem Pharmaceuticals Netherlands B.V. | Cyclohexapeptide |
-
2012
- 2012-12-21 SI SI201230815A patent/SI2922530T1/en unknown
- 2012-12-21 PT PT128105194T patent/PT2922530T/en unknown
- 2012-12-21 US US13/724,266 patent/US9636407B2/en active Active
- 2012-12-21 HU HUE12810519A patent/HUE032392T2/en unknown
- 2012-12-21 ES ES12810519.4T patent/ES2607646T3/en active Active
- 2012-12-21 LT LTEP12810519.4T patent/LT2922530T/en unknown
- 2012-12-21 WO PCT/US2012/071215 patent/WO2014081443A1/en active Application Filing
- 2012-12-21 EP EP12810519.4A patent/EP2922530B1/en active Active
- 2012-12-21 DK DK12810519.4T patent/DK2922530T3/en active
- 2012-12-21 PL PL12810519T patent/PL2922530T3/en unknown
- 2012-12-21 CA CA2888625A patent/CA2888625A1/en not_active Abandoned
-
2016
- 2016-03-29 HK HK16103590.0A patent/HK1215668A1/en unknown
- 2016-05-26 US US15/165,389 patent/US20160310597A1/en not_active Abandoned
- 2016-12-13 HR HRP20161703TT patent/HRP20161703T1/en unknown
- 2016-12-13 CY CY20161101284T patent/CY1120016T1/en unknown
- 2016-12-14 SM SM201600452T patent/SMT201600452B/en unknown
-
2017
- 2017-03-30 US US15/474,531 patent/US20170296667A1/en not_active Abandoned
-
2018
- 2018-04-06 US US15/947,453 patent/US20190105392A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
HK1215668A1 (en) | 2016-09-09 |
HRP20161703T1 (en) | 2017-03-10 |
CY1120016T1 (en) | 2018-12-12 |
US20190105392A1 (en) | 2019-04-11 |
US20160310597A1 (en) | 2016-10-27 |
US9636407B2 (en) | 2017-05-02 |
CA2888625A1 (en) | 2014-05-30 |
US20140142032A1 (en) | 2014-05-22 |
SMT201600452B (en) | 2017-01-10 |
WO2014081443A1 (en) | 2014-05-30 |
EP2922530B1 (en) | 2016-09-14 |
PT2922530T (en) | 2016-12-22 |
PL2922530T3 (en) | 2017-04-28 |
ES2607646T3 (en) | 2017-04-03 |
DK2922530T3 (en) | 2017-01-09 |
HUE032392T2 (en) | 2017-09-28 |
SI2922530T1 (en) | 2017-04-26 |
LT2922530T (en) | 2017-01-25 |
EP2922530A1 (en) | 2015-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190105392A1 (en) | Caspofungin Acetate Formulations | |
ES2686331T5 (en) | Lipopeptide compositions and related methods | |
JP5723030B2 (en) | Medicinal composition containing Mikafungin, an echinocandin antifungal agent, and production method and use thereof | |
EP3007681A1 (en) | Stable and water soluble pharmaceutical compositions comprising pemetrexed | |
JP6832281B2 (en) | Aqueous solution of vancomycin | |
WO2022129264A1 (en) | Aqueous solution | |
JP4142149B2 (en) | Vancomycin lyophilized formulation | |
US20220218784A1 (en) | Daptomycin Aqueous Formulations | |
WO2016170489A1 (en) | Pharmaceutical compositions of proteasome inhibitor | |
WO2017185030A1 (en) | Caspofungin formulation with low impurities | |
WO2022129263A1 (en) | Aqueous solution | |
US12005069B2 (en) | Bortezomib compositions | |
CN103330933B (en) | Pharmaceutical composition containing MFG or its salt | |
US20140323443A1 (en) | Tigecycline formulations | |
US20140275122A1 (en) | Voriconazole Formulations | |
WO2017037232A1 (en) | Anidulafungin formulations | |
US20240139282A1 (en) | Liquid dalbavancin compositions | |
CN103330932A (en) | Drug composition of micafungin or salt thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: FRESENIUS KABI USA, LLC, ILLINOIS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JIANG, ZHI-QIANG;BOWMAN, DAVID;PETERSON, JOEL;AND OTHERS;SIGNING DATES FROM 20130718 TO 20130724;REEL/FRAME:043529/0895 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |